Pathway analysis of the upregulated DEGs in the defined cancer cells (treated vs. at-diagnosis; FC ≥ 1.5 or ≤0.67, p < 10−20) revealed strong enrichment in the “p53 pathway,” as well as the “IFN-γ response” and several other immune/inflammation-related pathways in the MSigDB hallmark gene sets (Figure 5K). This evidence concerns the gene TP53 and cancer.